GCA
VCEL icon

Genesee Capital Advisors’s Vericel Corp VCEL Stock Holding History

Genesee Capital Advisors’s Portfolio VCEL Stock Details VCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-48,790
Closed -$854K – 108
2019
Q1 		$854K Buy
+48,790
New +$892K 1.03% 29

Other funds holding VCEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Genesee Capital Advisors's VCEL Position: Q2 2019 in Review

Genesee Capital Advisors sold out of Vericel Corp (VCEL) in Q2 2019, closing a stake of 48,790 shares — an estimated $854K sold.

Genesee Capital Advisors first reported a position in VCEL in Q1 2019 and held it in 1 quarter. The position peaked at $854K in Q1 2019. 137 funds tracked by Wall St. Rank hold VCEL as of Q2 2019.

  • Genesee Capital Advisors reported no remaining Vericel Corp position as of Q2 2019 after selling out during the quarter.
  • Genesee Capital Advisors sold 48,790 Vericel Corp shares in Q2 2019, an estimated $854K.
  • Genesee Capital Advisors first reported a position in Vericel Corp in Q1 2019 and held it in 1 quarter.
  • Genesee Capital Advisors's Vericel Corp position peaked at $854K in Q1 2019.
  • 137 funds tracked by Wall St. Rank held Vericel Corp as of Q2 2019.

Based on Genesee Capital Advisors's 13F filing for Q2 2019, filed 19 Jul 2019.